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inhibitors of Epidermal Growth Factor Receptor Tyrosine
Kinase
K Hemalatha*, K Sujatha, P Panneerselvam, K Girija
Email: hemalathampharm@gmail.com

Abstract
A series of novel 4-anilino quinazoline derivatives were designed and optimized with AutoDock 4.2 to investigate
the interaction between the target compounds and the amino acid residues of target protein Epidermal Growth
Factor Receptor-Tyrosine Kinase. The free energies of binding and inhibition constants (Ki) of the docked
ligands were calculated by the Lamarckian Genetic Algorithm (LGA). The docking results showed that the
compounds SGQ4, DMUQ5, 6AUQ6 and PTQ8 produced significant docking affinity for the protein Tyrosine
Kinase with the binding energy of -7.46, -7.31, -6.85 and -6.74 Kcal/mol, respectively compared to the standard
Erlotinib (Binding energy: -3.84 Kcal/mol). The molecular descriptor properties and toxicity profile were
predicted by the software. All the designed molecules passed the Lipinski rule of five successfully and they were
found to be safe. The studied compounds are a promising class of compounds with potential anti-cancer activity
against breast cancer cells and they can be recommended for further research to treat the disease. The prediction
of acute toxicity in rats has been carried out in oral and intravenous routes of administration using the GUSAR
program.
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Introduction
The risk of cancer increases significantly with age
and most cancers occur more commonly in developed
countries.1 There are over 100 different known
cancers that affect humans. The most common types
of cancer in males are lung cancer, prostate cancer,
colorectal cancer and stomach cancer, and in females
the most common types are breast cancer, colorectal
cancer, lung cancer and cervical cancer.1 In children,
acute lymphoblastic leukaemia and brain tumours
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are the most common except in Africa where nonHodgkin lymphoma occurs more often. In 2012,
about 165,000 children less than 15 years of age were
diagnosed with cancer. The rising trend of breast
cancer in both developed and developing countries
is a real threat challenging all efforts to screen,
prevent and treat the aspects that could contribute
to reducing breast cancer.. The most common type
of breast cancer is ductal carcinoma, which begins
in the lining of the milk ducts (thin tubes that carry
milk from the lobules of the breast to the nipple).2
Another type of breast cancer is lobular carcinoma,
which begins in the lobules (milk glands) of the
breast. The invasive breast cancer is a type of cancer
that spreads from where it began in the breast ducts
or lobules to the surrounding normal tissue. Breast
cancer occurs in both men and women, although
male breast cancer is rare.
The incidence of breast cancer is rising in India and
is now the second most common cancer diagnosed in

How to cite this article: Hemalatha K, Sujatha K, Panneerselvam P, Girija K. Molecular docking studies of 4-anilino quinazolines
as inhibitors of Epidermal Growth Factor Receptor Tyrosine Kinase. MJPS 2018; 4(1):17-25.

Manipal Journal of Pharmaceutical Sciences | March 2018 | Volume 4 | Issue 1

Published by Impressions@MAHE, 2022

17

1

